Pharmaceutical Product Development, LLC, announced on Friday that it was chosen by the Biomedical Advanced Research and Development Authority to be included in the Medical Countermeasure Clinical Studies Network.
PPD will assist BARDA and other members in the network in planning, performing, monitoring and analyzing Phase I-IV clinical studies of new drugs, vaccines and treatments for biomedical threats.
"PPD's inclusion in this vital network highlights our industry-leading efforts to support government research and development programs through our robust, end-to-end clinical research services," PPD Executive Vice President of Clinical Development Paul Colvin said. "We are excited at the prospect of deploying our world-class scientific expertise, innovative solutions, cutting-edge technology, flexible resources and operational efficiencies to help protect public health and the nation's health security."
PPD is a contract research organization that has provided study services such as drug discovery, development and research organization for more than 1,300 government and public health projects related to infectious diseases, vaccines, biodefense, autoimmune and asthma/allergic diseases. PPD has partnered with the pharmaceutical industry, biotechnology, medical device and academic sectors, as well as with the government.
PPD's contract with BARDA is indefinite delivery, indefinite quantity, with a performance period of at least two years and no more than five years.